Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

All aspects of prostate cancer evolution are closely related to androgen levels and the status of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways and AR, from castration-sensitive prostate cancer (CSPC) to castration-resistant prostate cancer (CRPC). Alterations...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Haozhe, Zhou, Yi, Xing, Zengzhen, Sah, Rajiv Kumar, Hu, Junqi, Hu, Hailiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655897/
https://www.ncbi.nlm.nih.gov/pubmed/36362304
http://dx.doi.org/10.3390/ijms232113521
_version_ 1784829299346374656
author Zhang, Haozhe
Zhou, Yi
Xing, Zengzhen
Sah, Rajiv Kumar
Hu, Junqi
Hu, Hailiang
author_facet Zhang, Haozhe
Zhou, Yi
Xing, Zengzhen
Sah, Rajiv Kumar
Hu, Junqi
Hu, Hailiang
author_sort Zhang, Haozhe
collection PubMed
description All aspects of prostate cancer evolution are closely related to androgen levels and the status of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways and AR, from castration-sensitive prostate cancer (CSPC) to castration-resistant prostate cancer (CRPC). Alterations in androgen metabolism and its response are one of the main reasons for prostate cancer drug resistance. In this review, we will introduce androgen metabolism, including how the androgen was synthesized, consumed, and responded to in healthy people and prostate cancer patients, and discuss how these alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.
format Online
Article
Text
id pubmed-9655897
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96558972022-11-15 Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance Zhang, Haozhe Zhou, Yi Xing, Zengzhen Sah, Rajiv Kumar Hu, Junqi Hu, Hailiang Int J Mol Sci Review All aspects of prostate cancer evolution are closely related to androgen levels and the status of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways and AR, from castration-sensitive prostate cancer (CSPC) to castration-resistant prostate cancer (CRPC). Alterations in androgen metabolism and its response are one of the main reasons for prostate cancer drug resistance. In this review, we will introduce androgen metabolism, including how the androgen was synthesized, consumed, and responded to in healthy people and prostate cancer patients, and discuss how these alterations in androgen metabolism contribute to the resistance to anti-androgen therapy. MDPI 2022-11-04 /pmc/articles/PMC9655897/ /pubmed/36362304 http://dx.doi.org/10.3390/ijms232113521 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhang, Haozhe
Zhou, Yi
Xing, Zengzhen
Sah, Rajiv Kumar
Hu, Junqi
Hu, Hailiang
Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
title Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
title_full Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
title_fullStr Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
title_full_unstemmed Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
title_short Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
title_sort androgen metabolism and response in prostate cancer anti-androgen therapy resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655897/
https://www.ncbi.nlm.nih.gov/pubmed/36362304
http://dx.doi.org/10.3390/ijms232113521
work_keys_str_mv AT zhanghaozhe androgenmetabolismandresponseinprostatecancerantiandrogentherapyresistance
AT zhouyi androgenmetabolismandresponseinprostatecancerantiandrogentherapyresistance
AT xingzengzhen androgenmetabolismandresponseinprostatecancerantiandrogentherapyresistance
AT sahrajivkumar androgenmetabolismandresponseinprostatecancerantiandrogentherapyresistance
AT hujunqi androgenmetabolismandresponseinprostatecancerantiandrogentherapyresistance
AT huhailiang androgenmetabolismandresponseinprostatecancerantiandrogentherapyresistance

Ejemplares similares